Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people achieved weight loss from a mean baseline body weight of 92.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Shares Soar as Experimental Shot Shows 22% Weight Loss
Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk amycretin data helps rebut concerns, says BofA
After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial,
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
Ozempic maker Novo Nordisk failed to disclose millions it paid to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
FierceBiotech4h
Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.